WEBINAR

Challenges, Shared Decision Making and Health Equity in Hemophilia and Real-World Patient Experience with HYMPAVZI (marstacimab-hncq)

Friday, April 25, 2025
2:00 pm - 3:00 pm EST

Faculty

Akshat Jain, MD, MPH

Director of the Inherited Bleeding Disorder
and Thrombosis Program & Director of Sickle
Cell Disease Program
Loma Linda University & Children’s Hospital

See Bio

Maya Bloomberg

Family Nurse Practitioner
Sylvester Comprehensive Cancer Center
and Jackson Memorial Hospital

See Bio

To educate attendees on challenges, shared decision making and health equity in hemophilia and introduce HYMPAVZI pen, dosage, administration, and real-world patient experience with HYMPAVZI.

INDICATIONS AND USAGE

IMPORTANT SAFETY INFORMATION

HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:

hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.

HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist and may increase the risk of thromboembolic complications. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or factor IX according to the product label is recommended.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

A serious adverse reaction of peripheral swelling occurred in one patient. Adverse reactions reported in ≥3% of patients treated with HYMPAVZI in clinical trials included injection site reaction (9% of patients); headache (7% of patients); pruritus (3% of patients).